Fri, January 6, 2023
Thu, January 5, 2023
Wed, January 4, 2023
Tue, January 3, 2023
Fri, December 30, 2022
Thu, December 29, 2022
Wed, December 28, 2022
Tue, December 27, 2022
Fri, December 23, 2022
Thu, December 22, 2022
Wed, December 21, 2022
Tue, December 20, 2022

Raghuram Selvaraju Maintained (BTAI) at Strong Buy with Decreased Target to $73 on, Jan 3rd, 2023


  Copy link into your clipboard //stocks-investing.news-articles.net/content/202 .. with-decreased-target-to-73-on-jan-3rd-2023.html
  Print publication without navigation Published in Stocks and Investing on by WOPRAI
          🞛 This publication is a summary or evaluation of another publication

Raghuram Selvaraju of HC Wainwright & Co., Maintained "BioXcel Therapeutics, Inc." (BTAI) at Strong Buy with Decreased Target from $85 to $73 on, Jan 3rd, 2023.

Raghuram has made no other calls on BTAI in the last 4 months.



There are 4 other peers that have a rating on BTAI. Out of the 4 peers that are also analyzing BTAI, 1 agrees with Raghuram's Rating of Hold. Following is the relevant analyst calls for the last 4 months


  • Corinne Jenkins of "Goldman Sachs" Upgraded from Strong Sell to Hold and Held Target at $16 on, Thursday, December 1st, 2022


These are the ratings of the 3 analyists that currently disagree with Raghuram


  • Graig Suvannavejh of "Mizuho" Maintained at Strong Buy with Decreased Target to $18 on, Wednesday, November 16th, 2022
  • Sumant Kulkarni of "Canaccord Genuity" Maintained at Strong Buy with Increased Target to $76 on, Friday, November 11th, 2022
  • Yatin Suneja of "Guggenheim" Maintained at Strong Buy with Decreased Target to $25 on, Friday, November 11th, 2022

Publication Contributing Sources